CLRM-18 SCREEN FAILURES IN PHASE III GLIOBLASTOMA CLINICAL TRIALS

Neurooncol Adv · 2022 · PMC9354194

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

These phase III trials universally require many participants, and the expenditure of phase III clinical trials is quite significant, with the median being 21.4 million dollars.

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.